Press Releases
Search
-
19 Oct 2023
Financial Information
bioMérieux makes strategic investment in Oxford Nanopore
Oxford Nanopore Technologies plc (LSE: ONT) (“Oxford Nanopore”), the company delivering a new generation of nanopore-based molecular sensing technology, and bioMérieux SA, a world leader in the field of in vitro diagnostics (“IVD”) today announce that bioMérieux is making an immediate £70M investment in Oxford Nanopore.
-
13 Oct 2023
Business & Solutions
bioMérieux announces CE-marking of VIDAS® TBI (GFAP, UCH-L1)
bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE-marking of VIDAS® TBI (GFAP, UCH-L1), a blood test to support assessment of patients with mild traumatic brain injury (mTBI), based on a unique combination of brain biomarkers: GFAP and UCH-L1*.
-
11 Oct 2023
Partnerships
Launch of a new industrial chair, in Lyon on viral respiratory infections
On October 11, 2023, the REVIDA Industrial Chair for Respiratory Infectious Diseases, led by researcher Sophie Trouillet-Assant (UCBL / HCL), was officially launched by Claude Bernard Lyon 1 University, Hospices Civils de Lyon, and bioMérieux, with the support of the Agence nationale de la recherche (National research agency, in France).
-
22 Sep 2023
Business & Solutions
bioMérieux submits Dual 510(k) and CLIA-waiver application to FDA for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel
bioMérieux, a world leader in the field of in vitro diagnostics, has submitted the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel to U.S. Food and Drug Administration (FDA) for a dual 510(k) clearance and CLIA1-waiver. This panel is already CE-marked (IVDD).
-
01 Sep 2023
Financial Information
First-Half 2023 Results
Consolidated sales amounted to €1,770 million in first-half 2023, a robust growth like-for-like of 8.3% from €1,658 million in the prior year.
-
26 Jul 2023
SITES - Press Release
bioMérieux Earns Nine Clinical Laboratory Awards for Excellence
bioMérieux was recently awarded nine IMV ServiceTrak™ Clinical Laboratory Awards in the categories of Immunoassay, ID/AST, and Blood Culture excellence.
-
27 Jun 2023
SITES - Press Release
Jennifer Zinn appointed Executive Vice President of Clinical Operations
Marcy-l’Étoile, France – June 27th, 2023. bioMérieux, a world leader in the field of in vitro diagnostics, announces the appointment of Jennifer Zinn as Executive Vice President of Clinical Operations...
-
14 Jun 2023
Appointments
bioMérieux evolves its governance
Marcy l’Étoile, France, June 14th, 2023 – bioMérieux, a world leader in the field of in vitro diagnostics, announces an evolution in its corporate governance. As of July 1st, 2023, Alexandre Mérieux w...
-
09 May 2023
SITES - Press Release
bioMérieux receives US FDA CLIA-waiver for the BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini
Marcy-l’Étoile (France), May 9th, 2023 – bioMérieux, a world leader in the field of in vitro diagnostics, has received U.S. Food and Drug Administration (FDA) Clinical Laboratory Improvement Amendment...
-
27 Apr 2023
SITES - Press Release
bioMérieux – First-Quarter 2023 Business Review
Marcy l’Étoile (France), April 27th, 2023 – bioMérieux today releases its business review for the three months ended March 31th, 2023. Consolidated sales totaled €906 million in the first quarter of 2...
-
14 Apr 2023
SITES - Press Release
Oxford Nanopore and bioMérieux to enter into a strategic partnership agreement
Oxford, UK and Marcy-l’Etoile, France, 14 April 2023: Oxford Nanopore Technologies plc (LSE: ONT) (“Oxford Nanopore”), the company delivering a new generation of nanopore-based molecular sensing techn...
-
13 Apr 2023
SITES - Press Release
bioMérieux receives US FDA 510(k) clearance for the BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini
Marcy-l’Étoile (France), April 13, 2023 – bioMérieux, a world leader in the field of in vitro diagnostics, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the fast and accura...
-
07 Apr 2023
SITES - Press Release
SPECIFIC REVEAL™ Rapid AST System, newly renamed VITEK® REVEAL™, submitted to US FDA for 510(k) clearance
Marcy l’Étoile, France, April 7 2023 – bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Admini...
-
05 Apr 2023
SITES - Press Release
bioMérieux launches BIOFIRE® FIREWORKS™, a cutting-edge, data-driven software solution
Marcy-l’Étoile, France – bioMérieux, a world leader in the field of in vitro diagnostics, launches BIOFIRE® FIREWORKS™, an innovative and integrated software solution for BIOFIRE® Systems optimizing l...
-
10 Mar 2023
SITES - Press Release
BioFire Defense partners with BARDA to accelerate development of the SPECIFIC REVEAL™ Rapid AST System
Marcy-l’Étoile, France – bioMérieux, a world leader in the field of in vitro diagnostics, announces that BioFire Defense, LLC, its affiliate and leader in pathogen detection systems for the U.S. Depar...